Desentum aims at defeating allergies

Allergy is one of the most common medical conditions. It has been estimated that within 40 years, as much as half of the world’s population will suffer from some form of allergy. Desentum, a spin-off company of VTT Technical Research Centre of Finland Ltd, is developing immunotherapy-based drugs (vaccines) for the treatment of allergies.